Loading
Life sciences · Journal article
Journal of Basic and Clinical Physiology and Pharmacology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Metabolically healthy obesity (MHO) is a heterogeneous phenotype characterized by preserved traditional metabolic markers despite excess adiposity. However, accumulating evidence suggests that MHO may not be uniformly benign and may confer increased long-term cardiovascular risk through inflammatory and adipose tissue–mediated mechanisms. This narrative review synthesizes contemporary evidence on cardiovascular risk in MHO, focusing on visceral adiposity, ectopic fat, and immune metabolic pathways. Literature published between January 2010 and December 2025 was identified through PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library. Across the reviewed evidence, MHO is frequently associated with the progression to metabolically unhealthy obesity, although transition rates and cardiovascular risk estimates vary according to MHO definitions. Visceral and ectopic fat are associated with subclinical atherosclerosis, coronary calcification, and cardiovascular events, including in individuals without overt metabolic abnormalities. Evidence regarding heart failure and ventricular dysfunction remains limited and inconsistent. Low-grade inflammation and adipose immune remodeling, including NLRP3 inflammasome activation, provide plausible mechanisms, although human evidence remains predominantly observational. Key gaps include inconsistent MHO definitions, limited longitudinal imaging and biomarker integration, population diversity, and lack of validated MHO-specific risk models. Standardized phenotyping and prospective validation of inflammation-based risk stratification are required.